Browse Studies — Arctuva

Phase 2

Cardioprotection With Dexrazoxane in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS), Myeloid Blast Phase of Chronic Myeloid Leukemia (CML), Ph+ AML, and Myeloid Blast Phase of Myeloproliferative Neoplasms

This phase II trial studies how well dexrazoxane hydrochloride works in preventing heart-related side effects of chemotherapy in participants with blood cancer…

Acute Myeloid LeukemiaBlast Phase Chronic Myelogenous Leukemia, BCR-ABL1 PositiveBlasts 10 Percent or More of Bone Marrow Nucleated Cells+4 more

Estimated

~$10 – $6,250

M.D. Anderson Cancer CenterNCT03589729

Phase 1

Phase 1 Study of Venetoclax/Azacitidine or Venetoclax in Combination With Ziftomenib or Standard Induction Cytarabine/Daunorubicin (7+3) Chemotherapy in Combination With Ziftomenib for the Treatment of Patients With Acute Myeloid Leukemia

Ziftomenib is an investigational drug in development for the treatment of patients with acute myeloid leukemia (AML) with certain genetic alterations. This pr…

Acute Myeloid LeukemiaMixed Lineage Leukemia Gene MutationRefractory AML+7 more

Estimated

~$10 – $8,750

Kura Oncology, Inc.NCT05735184

Phase 1

A Phase 1/2 Single-Center Trial Combining Venetoclax With G-CSF, Cladribine, Cytarabine, and Mitoxantrone (CLAG-M) for Patients With AML and High-Grade Myeloid Neoplasms

This phase I/II trial finds the best dose, side effects and how well giving venetoclax in combination with cladribine, cytarabine, granulocyte colony-stimulati…

Acute Biphenotypic LeukemiaAcute Myeloid LeukemiaMixed Phenotype Acute Leukemia+10 more

Estimated

~$10 – $6,250

University of WashingtonNCT04797767